Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Selected Financial Data
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Statement

Thermo Fisher Scientific Inc., selected items from income statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The financial performance indicators presented demonstrate a significant growth trajectory over the period examined, with notable fluctuations in certain years. Revenues, operating income, and net income attributable to Thermo Fisher Scientific Inc. all exhibited generally increasing trends, though the rate of growth varied considerably.

Revenue Growth
Revenues experienced substantial growth from 2005 to 2007, increasing from US$2,633 million to US$9,746 million. This growth rate slowed in subsequent years, with relatively modest increases between 2008 and 2014. A period of accelerated revenue growth commenced in 2015, continuing through 2021, reaching US$39,211 million. A slight decrease in revenue was observed in 2022, followed by stabilization in 2023 and a modest increase in 2024 and 2025.
Operating Income Trend
Operating income mirrored the revenue trend, with a dramatic increase between 2005 and 2007. Similar to revenues, operating income growth moderated between 2008 and 2014. The period from 2015 to 2021 saw a strong upward trend in operating income, culminating in US$10,028 million. Operating income decreased in 2022, and experienced moderate growth in 2023, 2024 and 2025.
Net Income Performance
Net income attributable to Thermo Fisher Scientific Inc. followed a similar pattern to revenue and operating income. A substantial increase occurred between 2005 and 2007, followed by a period of slower growth. The years 2015 through 2021 demonstrated significant net income growth, peaking at US$7,725 million in 2021. Net income decreased in 2022, and showed moderate growth in 2023, 2024 and 2025.

The correlation between revenues, operating income, and net income suggests effective cost management and operational efficiency, particularly during periods of rapid revenue expansion. The decrease observed in 2022 for all three metrics warrants further investigation to determine the underlying causes, though the subsequent stabilization and modest growth in 2023, 2024 and 2025 indicate a potential recovery. Overall, the financial indicators demonstrate a company experiencing substantial growth, with a recent period of stabilization following a period of rapid expansion.


Balance Sheet: Assets

Thermo Fisher Scientific Inc., selected items from assets, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Over the period examined, both current assets and total assets demonstrate significant growth, though with notable fluctuations. Initial growth is followed by periods of relative stability and then substantial increases, particularly in later years. The analysis below details these trends.

Current Assets Trend
Current assets experienced a dramatic increase between 2005 and 2006, rising from US$1,354 million to US$3,660 million. This growth plateaued between 2006 and 2007, with only a marginal change. A further increase occurred between 2007 and 2008, followed by a slight decline in 2010. A substantial jump is observed in 2013, reaching US$9,881 million, before decreasing in the following year. Fluctuations continue through 2016, with a subsequent increase to US$10,625 million in 2018. The most significant surge in current assets occurs between 2019 and 2020, increasing from US$11,893 million to US$21,957 million. A decrease is noted in 2021, followed by increases in 2022 and 2023, before a decline in 2024 and a final increase in 2025.
Total Assets Trend
Total assets mirrored the trend of current assets, with a substantial increase from US$4,252 million in 2005 to US$21,262 million in 2006. The period between 2006 and 2009 shows relative stability, with total assets fluctuating within a narrow range. A significant increase is then observed between 2009 and 2011, reaching US$26,834 million. Further growth continues through 2014, peaking at US$42,852 million, before a slight decrease in 2015. A considerable increase is seen between 2015 and 2017, reaching US$56,669 million. The period between 2017 and 2019 shows modest growth. A dramatic increase occurs between 2019 and 2020, with total assets reaching US$69,052 million. The largest increase in total assets occurs between 2020 and 2021, reaching US$95,123 million. Fluctuations are observed in 2022 and 2023, followed by a decrease in 2024 and a final increase in 2025.
Relationship between Current and Total Assets
Throughout the period, current assets consistently represent a substantial portion of total assets. While the exact percentage fluctuates, it generally remains significant, suggesting a considerable investment in short-term assets. The large increases in both current and total assets in the later years indicate a period of rapid expansion and potentially increased liquidity.

The observed trends suggest a company undergoing significant growth and potentially strategic shifts in asset allocation. The substantial increases in both current and total assets in the later years warrant further investigation to understand the underlying drivers, such as acquisitions, increased working capital needs, or changes in investment strategy.


Balance Sheet: Liabilities and Stockholders’ Equity

Thermo Fisher Scientific Inc., selected items from liabilities and stockholders’ equity, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The liabilities and stockholders’ equity of the company demonstrate significant changes over the period from 2005 to 2025. Current liabilities exhibit considerable fluctuation, while total obligations generally increased, particularly in the latter half of the observed timeframe. Stockholders’ equity shows a consistent upward trend, representing growing ownership stake.

Current Liabilities
Current liabilities began at US$792 million in 2005 and increased substantially to US$2,152 million in 2006. Following this peak, they decreased to US$1,540 million in 2008, then experienced moderate increases through 2011, reaching US$3,113 million. A subsequent decline to US$2,093 million in 2012 was followed by another increase, peaking at US$7,048 million in 2017. From 2018 through 2022, current liabilities fluctuated, reaching US$17,010 million in 2022 before decreasing to US$14,012 million in 2023 and US$13,332 million in 2024. A final increase is observed in 2025, reaching US$15,189 million. This pattern suggests a dynamic working capital management strategy or significant short-term financing activities.
Total Obligations
Total obligations show a general upward trend over the period. Starting at US$599 million in 2005, they increased to US$2,664 million by 2006. Growth continued, albeit at a slower pace, reaching US$2,195 million in 2007 and US$2,058 million in 2008. A notable increase occurred between 2010 and 2011, rising from US$2,137 million to US$7,028 million. Further substantial increases were observed between 2015 and 2017, culminating in US$21,008 million. From 2017 to 2022, total obligations increased significantly, peaking at US$34,870 million in 2021, before decreasing slightly to US$34,488 million in 2022. A further decrease to US$31,275 million in 2024 is followed by an increase to US$39,385 million in 2025. This indicates a growing reliance on debt financing or long-term commitments.
Total Stockholders’ Equity
Total stockholders’ equity demonstrates a consistent and substantial upward trend throughout the period. Beginning at US$2,793 million in 2005, it increased dramatically to US$13,912 million in 2006. Continued growth is evident, reaching US$14,488 million in 2007 and US$14,927 million in 2008. The equity continued to grow steadily, reaching US$15,431 million in 2009 and US$15,361 million in 2010. Further increases were observed through 2025, culminating in US$53,407 million. This consistent growth suggests strong profitability, effective reinvestment of earnings, and/or successful equity offerings.

The increasing trend in stockholders’ equity, coupled with the fluctuating but generally increasing total obligations, suggests a company actively utilizing both equity and debt to finance its operations and growth. The volatility in current liabilities warrants further investigation to understand the underlying drivers and potential risks associated with short-term liquidity.


Cash Flow Statement

Thermo Fisher Scientific Inc., selected items from cash flow statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


The cash flow statement reveals significant fluctuations across the observed period. Overall, operating activities consistently generate positive cash flow, while investing and financing activities demonstrate more variable performance, often involving substantial cash outflows or inflows depending on the year.

Operating Activities
Net cash provided by operating activities generally increased over the period, exhibiting a particularly strong surge between 2005 and 2007. Growth continued, albeit at a more moderate pace, through 2019. A substantial increase is observed in 2020, followed by a slight decrease in 2022 and 2023, before stabilizing in 2024 and a further decrease in 2025. The values consistently remain positive, indicating a healthy core business generating cash.
Investing Activities
Net cash flow from investing activities is highly volatile. Significant cash outflows are prevalent, particularly in 2006, 2008, 2009, 2011, 2014, and 2017. The largest outflow occurs in 2021, reaching a substantial negative value. There are periods of cash inflow, notably in 2006 and 2011, but these are less frequent and generally smaller in magnitude than the outflows. The pattern suggests substantial and ongoing investment in the business, potentially through acquisitions or capital expenditures. A decrease in outflow is observed in 2024 and 2025.
Financing Activities
Net cash flow from financing activities also demonstrates considerable variability. Positive cash flows are seen in 2005, 2011, 2014, 2016, and 2017, potentially representing periods of debt issuance or equity raises. Conversely, significant cash outflows occur in 2006, 2009, 2010, and 2025, likely due to debt repayment, share repurchases, or dividend payments. The largest outflow is observed in 2025. The fluctuations suggest active management of the capital structure.

The interplay between these three activities reveals a complex financial profile. The consistent positive operating cash flow appears to fund substantial investments and fluctuating financing needs. The large negative cash flow from investing activities in 2021 warrants further investigation to understand the specific drivers of that outflow. The significant outflow from financing activities in 2025 could indicate a major restructuring of the company’s debt or equity.

Overall, the company demonstrates a capacity to generate cash from its operations, but also engages in significant capital allocation activities, resulting in a dynamic cash flow profile.


Per Share Data

Thermo Fisher Scientific Inc., selected data per share, long-term trends

US$

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1, 2, 3 Data adjusted for splits and stock dividends.


The per share earnings figures demonstrate a generally positive trajectory over the observed period. Basic and diluted earnings per share exhibited volatility in the earlier years, from 2005 to 2009, before establishing a consistent upward trend. Dividend per share, initiated in 2012, has also shown consistent growth.

Earnings Per Share (Basic & Diluted)
From 2005 to 2007, basic earnings per share fluctuated, moving from US$1.38 to US$0.86, then increasing to US$1.81. A similar pattern is observed in diluted earnings per share. The period between 2008 and 2011 shows a steady increase in both basic and diluted earnings per share, rising from US$2.38 and US$2.29 respectively, to US$3.49 and US$3.46. Growth continued through 2019, reaching US$9.24 and US$9.17 for basic and diluted earnings per share. A significant surge occurred in 2020, with both metrics reaching US$16.09 and US$15.96, likely influenced by external factors. While remaining high, both metrics experienced a slight decline in 2022, before stabilizing and showing modest growth in 2023 and 2024. The difference between basic and diluted earnings per share remained consistently small throughout the period.
Dividend Per Share
Dividend payments commenced in 2012 at US$0.54 per share. From 2012 through 2025, the dividend per share consistently increased. The growth was incremental from 2012 to 2016, increasing to US$0.60. The rate of increase accelerated from 2016, reaching US$0.68 in 2018, US$0.76 in 2019, US$0.88 in 2020, US$1.04 in 2021, US$1.20 in 2022, and continuing to US$1.40 in 2023, US$1.56 in 2024 and US$1.72 in 2025. This demonstrates a commitment to returning value to shareholders through increasing dividend distributions.

Overall, the company demonstrates a pattern of increasing profitability, as evidenced by the growth in earnings per share, coupled with a consistent and growing dividend payout. The substantial increase in earnings per share in 2020 warrants further investigation to understand the underlying drivers. The consistent dividend growth suggests financial stability and confidence in future earnings potential.